MEDNAX (NYSE:MD) has been assigned a $55.00 price target by stock analysts at SunTrust Banks in a report issued on Thursday. The brokerage presently has a “hold” rating on the stock. SunTrust Banks’ price target indicates a potential upside of 4.70% from the company’s previous close.
Several other research firms have also weighed in on MD. Piper Jaffray Companies assumed coverage on shares of MEDNAX in a research report on Wednesday, December 13th. They set an “overweight” rating and a $58.00 price target for the company. Jefferies Group restated a “hold” rating and set a $46.00 price target on shares of MEDNAX in a research report on Tuesday, October 3rd. Robert W. Baird restated a “hold” rating and set a $47.00 price target on shares of MEDNAX in a research report on Sunday, September 3rd. KeyCorp set a $51.00 price target on shares of MEDNAX and gave the company a “buy” rating in a research report on Wednesday, November 1st. Finally, Citigroup reduced their price target on shares of MEDNAX from $52.00 to $47.00 and set a “neutral” rating for the company in a research report on Friday, November 3rd. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $53.82.
MEDNAX (MD) opened at $52.53 on Thursday. The firm has a market cap of $4,844.79, a PE ratio of 15.82, a P/E/G ratio of 1.67 and a beta of 0.40. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 0.62. MEDNAX has a 1 year low of $40.56 and a 1 year high of $72.13.
In other MEDNAX news, insider John C. Pepia sold 3,000 shares of the company’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $51.58, for a total transaction of $154,740.00. Following the sale, the insider now directly owns 35,569 shares of the company’s stock, valued at $1,834,649.02. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Cesar L. Alvarez sold 10,668 shares of the stock in a transaction dated Friday, November 3rd. The stock was sold at an average price of $42.59, for a total transaction of $454,350.12. Following the completion of the sale, the director now directly owns 44,215 shares in the company, valued at $1,883,116.85. The disclosure for this sale can be found here. 2.40% of the stock is owned by corporate insiders.
Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. lifted its holdings in shares of MEDNAX by 0.3% in the second quarter. BlackRock Inc. now owns 8,257,495 shares of the company’s stock worth $498,505,000 after buying an additional 28,155 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of MEDNAX by 0.5% in the second quarter. Vanguard Group Inc. now owns 7,551,130 shares of the company’s stock worth $455,862,000 after buying an additional 38,645 shares in the last quarter. Thompson Siegel & Walmsley LLC lifted its holdings in shares of MEDNAX by 19.7% in the third quarter. Thompson Siegel & Walmsley LLC now owns 2,598,925 shares of the company’s stock worth $112,065,000 after buying an additional 428,184 shares in the last quarter. Nordea Investment Management AB lifted its holdings in shares of MEDNAX by 4.8% in the third quarter. Nordea Investment Management AB now owns 2,323,695 shares of the company’s stock worth $100,198,000 after buying an additional 106,883 shares in the last quarter. Finally, Earnest Partners LLC lifted its holdings in shares of MEDNAX by 0.7% in the third quarter. Earnest Partners LLC now owns 1,494,374 shares of the company’s stock worth $64,437,000 after buying an additional 11,037 shares in the last quarter. 98.43% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by American Banking and Market News and is the property of of American Banking and Market News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/12/22/mednax-md-given-a-55-00-price-target-at-suntrust-banks.html.
MEDNAX Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
